Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT plus anlotinib for advanced non-small cell lung cancer
ChiCTR2100043854Phase 4Recruiting
- Sponsor
- Pingmei Shenma Medical Group General Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Pingmei Shenma Medical Group General Hospital. Primary endpoints: Progression-free survival and Disease control rate (ORR). Started Mar 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100043854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043854.